Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Ocera Therapeutics Inc (NASDAQ:OCRX)

3.79
Delayed Data
As of 3:59pm ET
 +0.16 / +4.41%
Today’s Change
3.30
Today|||52-Week Range
8.10
-40.50%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Pharmaceuticals: Other
MARKET CAP
$72.2M

Company Description

Ocera Therapeutics, Inc. is a clinical stage biopharmaceutical company. It focuses on the development and commercialization of OCR-002 ornithine phenylacetate. The OCR-002 is an ammonia scavenger which is used to treat hyperammonemia and associated hepatic encephalopathy in patients with liver cirrhosis, acute liver failure and acute liver injury. The company was founded by Wu Xiaoyun and John C. Kappes on January 12, 1998 and is headquartered in Palo Alto, CA.

Contact Information

Ocera Therapeutics, Inc.
525 University Avenue
Palo Alto California 94301
P:(650) 475-0150
Investor Relations:
(919) 328-1109

Employees

Shareholders

Other institutional27.22%
Mutual fund holders2.89%
Individual stakeholders2.10%

Top Executives

Linda S. GraisPresident, Chief Executive Officer & Director
Michael ByrnesChief Financial Officer, Treasurer & VP-Finance
Gaurav AggarwalChief Business Officer
Susan P. SharpeHead-Investor Relations